Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
Department of Medical Rehabilitation, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
Front Immunol. 2023 Jan 26;14:1069894. doi: 10.3389/fimmu.2023.1069894. eCollection 2023.
IFN-α intervention may block SARS-CoV-2 replication and normalize the deregulated innate immunity of COVID-19.
This meta-analysis aimed to investigate the efficacy of interferon IFN-α-containing regimens when treating patients with moderate-to-severe COVID-19.
PubMed, SCOPUS, and ClinicalTrials.gov were searched from inception to 15 January 2022. A systematic literature search was conducted by applying relevant terms for 'COVID-19' and 'interferon-α'. The primary outcome enclosed the all-cause hospital mortality. The secondary outcomes constituted the length of hospital stay; hospital discharge; nucleic acid negative conversion.
Eleven studies are enclosed in the meta-analysis. No significant difference in the all-cause mortality rate was found between the study and control groups (OR 0.2; 95% CI 0.05-1.2; I = 96%). The implementation of interferon did not influence such outcomes as the length of hospital stay (OR 0.9; 95% CІ, 0.3-2.6; I 91%), nucleic acid negative conversion (OR 0.8; 95% CI, 0.04-17.2; I 94%). Nevertheless, IFN-α treatment resulted in a higher number of patients discharged from the hospital (OR 26.6; 95% CІ, 2.7-254.3; I = 95%).
Thus, IFN-α does not benefit the survival of hospitalized COVID-19 patients but may increase the number of patients discharged from the hospital.
www.crd.york.ac.uk/prospero, identifier (CRD42022374589).
IFN-α 干预可能阻断 SARS-CoV-2 的复制并使 COVID-19 失调的固有免疫正常化。
本荟萃分析旨在研究包含干扰素 IFN-α 的方案治疗中重度 COVID-19 患者的疗效。
从创建到 2022 年 1 月 15 日，检索了 PubMed、SCOPUS 和 ClinicalTrials.gov。通过应用有关“COVID-19”和“干扰素-α”的相关术语进行系统文献检索。主要结局包括全因住院死亡率。次要结局包括住院时间、出院、核酸转阴。
荟萃分析纳入了 11 项研究。研究组和对照组的全因死亡率无显著差异（OR 0.2；95%CI 0.05-1.2；I = 96%）。干扰素的实施并未影响住院时间（OR 0.9；95%CI 0.3-2.6；I 91%）、核酸转阴（OR 0.8；95%CI 0.04-17.2；I 94%）等结局。然而，IFN-α 治疗导致更多的患者出院（OR 26.6；95%CI 2.7-254.3；I = 95%）。
因此，IFN-α 不能改善住院 COVID-19 患者的生存率，但可能会增加出院患者的数量。
Zotero 插件
